申请人:Topivert Pharma Limited
公开号:US10392346B2
公开(公告)日:2019-08-27
There are provided compounds of formula IIb,
wherein:
LG1 represents imidazolyl, chloro, or aryloxy; and
Z1 represents a structural fragment of formula V:
wherein R2 to R4, R5a, L and X1 to X3 have meanings given in the description, or a salt or protected derivative thereof, wherein said protected derivative is a compound in which the carboxyl moiety of R4 is protected as a C1-8 alkyl ester. The compounds have antiinflammatory activity, for example through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.
提供了式 IIb 的化合物、
其中
LG1 代表咪唑基、氯基或芳氧基;以及
Z1 代表式 V 的结构片段:
其中 R2 至 R4、R5a、L 和 X1 至 X3 具有说明中给出的含义,或其盐或受保护衍生物,其中所述受保护衍生物是 R4 的羧基作为 C1-8 烷基酯受保护的化合物。这些化合物具有抗炎活性,例如通过抑制以下一种或多种成员:p38 丝裂原活化蛋白激酶家族;Syk 激酶;以及酪氨酸激酶 Src 家族成员),可用于治疗,包括药物组合,特别是用于治疗炎症性疾病,包括肺部、眼部和肠道的炎症性疾病。